Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karin Pettersson is active.

Publication


Featured researches published by Karin Pettersson.


Human Reproduction | 2009

Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue

Victoria Keros; Susanna Xella; Kjell Hultenby; Karin Pettersson; Maryam Sheikhi; Annibale Volpe; Julius Hreinsson; Outi Hovatta

BACKGROUND Controlled-rate freezing of ovarian cortical tissue for preservation of fertility among young women facing chemo- or radio-therapy is a widely accepted procedure. To improve the method for cryopreservation of ovarian tissue, particularly the stroma, we carried out a systematic comparison of vitrification versus slow programmed freezing. METHODS Ovarian tissue from 20 women, donated during Caesarean section, was used for parallel comparison of survival and detailed light and electron microscopic (EM) morphology of oocytes, granulosa cells and ovarian stroma after freezing (slow freezing and vitrification), thawing and 24-h culture. Using tissue obtained from the same patient, we compared four cryopreservation protocols and fresh tissue. The cryoprotectants used in slow freezing were 1,2-propanediol (PrOH)-sucrose and ethylene glycol (EG)-sucrose. For vitrification, tissues were incubated for 5 or 10 min in three solutions containing a combination of dimethyl sulphoxide (DMSO), PrOH, EG and polyvinylpyrrolidone (PVP). RESULTS Cryopreservation using controlled-rate freezing and vitrification preserved the morphological characteristics of ovarian tissue generally well. As revealed by morphological analysis, particularly EM, the ovarian stroma was significantly better preserved after vitrification than after slow freezing (P < 0.001). The follicles were similarly preserved after all freezing methods. CONCLUSIONS Vitrification using a combination of PrOH, EG, DMSO and PVP was comparable to slow freezing in terms of preserving follicles in human ovarian tissue. Ovarian stroma had significantly better morphological integrity after vitrification than after controlled-rate freezing.


Acta Obstetricia et Gynecologica Scandinavica | 2014

Causes of stillbirth at different gestational ages in singleton pregnancies.

Hanna Stormdal Bring; Ingela hulthén Varli; Marius Kublickas; Nikos Papadogiannakis; Karin Pettersson

To compare causes of stillbirth in preterm and term pregnancies.


Aids Patient Care and Stds | 2012

Rapid Decline in HIV Viral Load When Introducing Raltegravir-Containing Antiretroviral Treatment Late in Pregnancy

Katarina Westling; Karin Pettersson; Anneli Kaldma; Lars Navér

Antenatal screening program for HIV has been in use in Sweden since 1987 with a 95-98% acceptance rate. Screening is performed during gestational week 10-12 and antiretroviral treatment (ART) to prevent mother-to-child transmission (MTCT) is initiated at gestational week 14-18. However, some women present with HIV in late pregnancy and additional treatment are wanted to achieve viral suppression before delivery. The integrase inhibitor raltegravir has a favorable pharmacokinetic profile and a capacity to rapidly decrease the viral load (VL). We describe four women presenting as HIV positive late in pregnancy, their ART, and outcome for the mother and child. Four women were discovered as HIV positive late in pregnancy, of 7 discovered in the antenatal screening programme in Stockholm County Council during 2011. Raltegravir was added to standard ART. The mean VL at presentation was 217,000 copies per milliliter (range, 65,000-637,000). A rapid decline of HIV RNA was observed in all cases, one woman treated with ART for only 8 days prior to delivery. The mean VL decline per week was 1.12 log (range, 0.94-1.22), which is estimated to occur (based on literature) after 1-2 months with standard ART. No side effects due to raltegravir were observed in mothers or infants. Caesarean section was performed in all cases, and the women did not breastfeed. No infant was infected. This report suggests that raltegravir added to standard antiretroviral treatment would be an option for women presenting with HIV in late pregnancy.


Journal of Maternal-fetal & Neonatal Medicine | 2014

Real-time PCR-assay in the delivery suite for determination of group B streptococcal colonization in a setting with risk-based antibiotic prophylaxis

Stellan Håkansson; Karin Källén; Maria Bullarbo; Per-Åke Holmgren; Katarina Bremme; Åsa Larsson; Margareta Norman; Håkan Norén; Catharina Ortmark-Wrede; Karin Pettersson; Sissel Saltvedt; Birgitta Sondell; Magdalena Tokarska; Anna von Vultee; Bo Jacobsson

Abstract Objective: Intrapartum antibiotic prophylaxis (IAP) reduces the incidence of neonatal early onset group B streptococcal infections. The present study investigated if an automated PCR-assay, used bedside by the labor ward personnel was manageable and could decrease the use of IAP in a setting with a risk-based IAP strategy. Methods: The study comprises two phases. Phase 1 was a multicenter, randomized, controlled trial. Women with selected risk-factors were allocated either to PCR-IAP (prophylaxis given if positive or indeterminate) or IAP. A vaginal/rectal swab and superficial swabs from the neonate for conventional culture were also obtained. Phase 2 was non-randomized, assessing an improved version of the assay. Results: Phase 1 included 112 women in the PCR-IAP group and 117 in the IAP group. Excluding indeterminate results, the assay showed a sensitivity of 89% and a specificity of 90%. In 44 % of the PCR assays the result was indeterminate. The use of IAP was lower in the PCR group (53 versus 92%). Phase 2 included 94 women. The proportion of indeterminate results was reduced (15%). The GBS colonization rate was 31%. Conclusion: The PCR assay, in the hands of labor ward personnel, can be useful for selection of women to which IAP should be offered.


Scandinavian Journal of Infectious Diseases | 2014

Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy

Jan Albert; Torsten Berglund; Magnus Gisslén; Peter Gröön; Anders Sönnerborg; Anders Tegnell; Anders Alexandersson; Ingela Berggren; Anders Blaxhult; Maria Brytting; Christina Carlander; Johan Carlson; Leo Flamholc; Per Follin; Axana Haggar; Frida I Hansdotter; Filip Josephson; Olle Karlström; Fredrik Liljeros; Lars Navér; Karin Pettersson; Veronica Svedhem Johansson; Bo Svennerholm; Petra Tunbäck; Katarina Widgren

Abstract The modern medical treatment of HIV with antiretroviral therapy (ART) has drastically reduced the morbidity and mortality in patients infected with this virus. ART has also been shown to reduce the transmission risk from individual patients as well as the spread of the infection at the population level. This position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy is based on a workshop organized in the fall of 2012. It summarizes the latest research and knowledge on the risk of HIV transmission from patients on ART, with a focus on the risk of sexual transmission. The risk of transmission via shared injection equipment among intravenous drug users is also examined, as is the risk of mother-to-child transmission. Based on current knowledge, the risk of transmission through vaginal or anal intercourse involving the use of a condom has been judged to be minimal, provided that the person infected with HIV fulfils the criteria for effective ART. This probably also applies to unprotected intercourse, provided that no other sexually transmitted infections are present, although it is not currently possible to fully support this conclusion with direct scientific evidence. ART is judged to markedly reduce the risk of blood-borne transmission between people who share injection equipment. Finally, the risk of transmission from mother to child is very low, provided that ART is started well in advance of delivery.


Acta Obstetricia et Gynecologica Scandinavica | 2011

Mothers’ attitudes towards perinatal autopsy after stillbirth

Carola Holste; Christina Pilo; Karin Pettersson; Ingela Rådestad; Nikos Papadogiannakis

We investigated mothers’ attitudes to autopsy of their stillborn baby and their experiences concerning information and treatment in relation to their loss in an observational study. Data were collected by postal questionnaires and telephone calls. Fifty‐four of 72 mothers (76%) replied. Fifty‐one (94%) received information from a physician about the possibility of having an autopsy; three (6%) did not get any information. The autopsy rate was 83% (n= 45). Thirty‐six of 45 (80%) received adequate information about results. Twenty‐five (56%) were pleased with how results were presented. Eleven (24%) were positive about individual contact with the pathologist who performed the autopsy. Fifty‐one (94%) stated that their decision concerning autopsy was right. Mothers do not regret their decision concerning perinatal autopsy but they do not always receive thorough and timely information concerning autopsy and its results. Personal contact with the perinatal pathologist might help with specific questions both before and after autopsy.


Seminars in Fetal & Neonatal Medicine | 2017

Classification of causes and associated conditions for stillbirths and neonatal deaths

Vicki Flenady; Aleena M Wojcieszek; David Ellwood; Susannah Hopkins Leisher; Jan Jaap Erwich; Elizabeth S. Draper; Elizabeth M. McClure; Hanna E. Reinebrant; Jeremy Oats; Lesley McCowan; Alison L. Kent; Glenn Gardener; Adrienne Gordon; David Tudehope; Dimitrios Siassakos; Claire Storey; Jane Zuccollo; Jane E. Dahlstrom; Katherine J. Gold; Sanne J. Gordijn; Karin Pettersson; Vicki Masson; Robert Clive Pattinson; Jason Gardosi; T. Yee Khong; J Frederik Frøen; Robert M. Silver

Accurate and consistent classification of causes and associated conditions for perinatal deaths is essential to inform strategies to reduce the five million which occur globally each year. With the majority of deaths occurring in low- and middle-income countries (LMICs), their needs must be prioritised. The aim of this paper is to review the classification of perinatal death, the contemporary classification systems including the World Health Organizations International Classification of Diseases - Perinatal Mortality (ICD-PM), and next steps. During the period from 2009 to 2014, a total of 81 new or modified classification systems were identified with the majority developed in high-income countries (HICs). Structure, definitions and rules and therefore data on causes vary widely and implementation is suboptimal. Whereas system testing is limited, none appears ideal. Several systems result in a high proportion of unexplained stillbirths, prompting HICs to use more detailed systems that require data unavailable in low-income countries. Some systems appear to perform well across these different settings. ICD-PM addresses some shortcomings of ICD-10 for perinatal deaths, but important limitations remain, especially for stillbirths. A global approach to classification is needed and seems feasible. The new ICD-PM system is an important step forward and improvements will be enhanced by wide-scale use and evaluation. Implementation requires national-level support and dedicated resources. Future research should focus on implementation strategies and evaluation methods, defining placental pathologies, and ways to engage parents in the process.


British Journal of Obstetrics and Gynaecology | 2018

Making stillbirths visible: a systematic review of globally reported causes of stillbirth

Hanna E. Reinebrant; Susannah Hopkins Leisher; Michael Coory; S. Henry; Aleena M Wojcieszek; Glenn Gardener; Rohan Lourie; David Ellwood; Z. Teoh; Emma Allanson; Hannah Blencowe; Elizabeth S. Draper; Johannes Erwich; J. F. Froen; Jason Gardosi; Katherine J. Gold; Sanne J. Gordijn; Adrienne Gordon; Alexander Heazell; T. Y. Khong; Fleurisca J. Korteweg; Joy E Lawn; Elizabeth M. McClure; Jeremy Oats; Robert Clive Pattinson; Karin Pettersson; Dimitrios Siassakos; Robert M. Silver; Gcs Smith; Özge Tunçalp

Stillbirth is a global health problem. The World Health Organization (WHO) application of the International Classification of Diseases for perinatal mortality (ICD‐PM) aims to improve data on stillbirth to enable prevention.


Fetal Diagnosis and Therapy | 2014

Molecular and Cytogenetic Analysis in Stillbirth: Results from 481 Consecutive Cases

Ellika Sahlin; Peter Gustavsson; Agne Liedén; Nikos Papadogiannakis; Linus Bjäreborn; Karin Pettersson; Magnus Nordenskjöld; Erik Iwarsson

Introduction: The underlying causes of stillbirth are heterogeneous and in many cases unexplained. Our aim was to conclude clinical results from karyotype and quantitative fluorescence-polymerase chain reaction (QF-PCR) analysis of all stillbirths occurring in Stockholm County between 2008 and 2012. By screening a subset of cases, we aimed to study the possible benefits of chromosomal microarray (CMA) in the analysis of the etiology of stillbirth. Methods: During 2008-2012, 481 stillbirths in Stockholm County were investigated according to a clinical protocol including karyotype or QF-PCR analysis. CMA screening was performed on a subset of 90 cases, corresponding to all stillbirths from 2010 without a genetic diagnosis. Results: Chromosomal aberrations were detected by karyotype or QF-PCR analysis in 7.5% of the stillbirths. CMA analysis additionally identified two known syndromes, one aberration disrupting a known disease gene, and 26 variants of unknown significance. Furthermore, CMA had a significantly higher success rate than karyotyping (100 vs. 80%, p < 0.001). Discussion: In the analysis of stillbirth, conventional karyotyping is prone to failure, and QF-PCR is a useful complement. We show that CMA has a higher success rate and aberration detection frequency than these methods, and conclude that CMA is a valuable tool for identification of chromosomal aberrations in stillbirth.


BMJ Open | 2017

Wait a minute? An observational cohort study comparing iron stores in healthy Swedish infants at 4 months of age after 10-, 60- and 180-second umbilical cord clamping

Ulrica Askelöf; Ola Andersson; Magnus Domellöf; Anders Fasth; Boubou Hallberg; Lena Hellström-Westas; Karin Pettersson; Magnus Westgren; Ingela E Wiklund; Cecilia Götherström

Background and objective Umbilical cord blood (UCB) is a valuable stem cell source used for transplantation. Immediate umbilical cord (UC) clamping is widely practised, but delayed UC clamping is increasingly advocated to reduce possible infant anaemia. The aim of this study was to investigate an intermediate UC clamping time point and to evaluate iron status at the age of 4 months in infants who had the UC clamped after 60 s and compare the results with immediate and late UC clamping. Design Prospective observational study with two historical controls. Setting A university hospital in Stockholm, Sweden, and a county hospital in Halland, Sweden. Methods Iron status was assessed at 4 months in 200 prospectively recruited term infants whose UC was clamped 60 s after birth. The newborn baby was held below the uterine level for the first 30 s before placing the infant on the mother’s abdomen for additional 30 s. The results were compared with data from a previously conducted randomised controlled trial including infants subjected to UC clamping at ≤10 s (n=200) or ≥180 s (n=200) after delivery. Results After adjustment for age differences at the time of follow-up, serum ferritin concentrations were 77, 103 and 114 µg/L in the 10, 60 and 180 s groups, respectively. The adjusted ferritin concentration was significantly higher in the 60 s group compared with the 10 s group (P=0.002), while the difference between the 60 and 180 s groups was not significant (P=0.29). Conclusion In this study of healthy term infants, 60 s UC clamping with 30 s lowering of the baby below the uterine level resulted in higher serum ferritin concentrations at 4 months compared with 10 s UC clamping. The results suggest that delaying the UC clamping for 60 s reduces the risk for iron deficiency. Trial registration number NCT01245296.

Collaboration


Dive into the Karin Pettersson's collaboration.

Top Co-Authors

Avatar

Ingela Rådestad

Mälardalen University College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lars Navér

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nikos Papadogiannakis

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge